Showing results (31-40 of 127) with videos related to

Sort By:
Pageof 13
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 10, 2013
Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis CZobair M Younossi, Maria Stepanova, Linda Henry, et al.
Hepatology Communications|May 19, 2026
Effect of tiomolibdate choline on copper balance in patients with Wilson disease: An open-label phase 2 trialAftab Ala, Thomas D Sandahl, Karl H Weiss, et al.
Antimicrobial Agents and Chemotherapy|November 4, 2025
Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infectionAnna Maria Geretti, Alexandre Sostelly, Simon Buatois, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 4, 2016
No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus InfectionMark S Sulkowski, Wan-Long Chuang, Jia-Horng Kao, et al.
Hepatology International|August 12, 2009
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 updateYun-Fan Liaw, Nancy Leung, Jia-Horng Kao, et al.
European Journal of Clinical Pharmacology|October 21, 2018
Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairmentMatthew P Kosloski, Haoyu Wang, David Pugatch, et al.
Journal of Hepatology|February 21, 2006
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis CDaniele Prati, Mitchell L Shiffman, Moisés Diago, et al.
Alimentary Pharmacology & Therapeutics|May 23, 2022
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infectionTahrima Kayes, Harry Crane, Allison Symonds, et al.
Gastroenterology|December 4, 2004
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levelsStefan Zeuzem, Moisés Diago, Edward Gane, et al.
Hepatology (Baltimore, Md.)|September 18, 2016
Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II studyMarianne Martinello, Edward Gane, Margaret Hellard, et al.
Pageof 13